Biopharmaceutical company Alkermes plc (Nasdaq:ALKS) revealed on Monday the planned resignation of Jim Robinson with effect from 19 April 2019 for personal reasons.
Currently, Robinson serves as the president and chief operating officer in the company.
Alkermes develops medicines for the treatment of central nervous system (CNS) diseases.It has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology.
Headquartered in Dublin, Ireland, the company has an R&D centre in Waltham, Massachusetts, a research and manufacturing facility in Athlone, Ireland and a manufacturing facility in Wilmington, Ohio.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials